Healthcare provider profile · identity verified

Nahid Memon, MD

Internal Medicine · TRENTON, NJ · NPI 1962427922

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	223	39
Eliquis	Apixaban	167	17
Pantoprazole Sodium	Pantoprazole Sodium	144	24
Levothyroxine Sodium	Levothyroxine Sodium	134	20
Metoprolol Tartrate	Metoprolol Tartrate	121	20
Amlodipine Besylate	Amlodipine Besylate	119	26
Escitalopram Oxalate	Escitalopram Oxalate	114	15
Losartan Potassium	Losartan Potassium	106	15
Gabapentin	Gabapentin	104	18
Furosemide	Furosemide	101	17
Famotidine	Famotidine	85	13
Trazodone Hcl	Trazodone Hcl	84	12
Clopidogrel	Clopidogrel Bisulfate	80	12
Metformin Hcl	Metformin Hcl	80	12
Carvedilol	Carvedilol	71	11
Metoprolol Succinate	Metoprolol Succinate	66	13
Carbidopa-Levodopa	Carbidopa/Levodopa	64	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	58	suppressed
Jardiance	Empagliflozin	57	suppressed
Januvia	Sitagliptin Phosphate	54	suppressed
Donepezil Hcl	Donepezil Hcl	50	suppressed
Divalproex Sodium	Divalproex Sodium	46	suppressed
Potassium Chloride	Potassium Chloride	46	suppressed
Montelukast Sodium	Montelukast Sodium	45	suppressed
Sertraline Hcl	Sertraline Hcl	45	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	43	suppressed
Propranolol Hcl	Propranolol Hcl	42	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	40	suppressed
Latanoprost	Latanoprost	38	suppressed
Lisinopril	Lisinopril	38	suppressed
Procrit	Epoetin Alfa	38	suppressed
Mirtazapine	Mirtazapine	36	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	33	suppressed
Prednisone	Prednisone	31	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	30	suppressed
Levetiracetam	Levetiracetam	30	suppressed
Baclofen	Baclofen	29	suppressed
Memantine Hcl	Memantine Hcl	27	suppressed
Repaglinide	Repaglinide	25	suppressed
Vascepa	Icosapent Ethyl	25	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	24	suppressed
Hydralazine Hcl	Hydralazine Hcl	24	suppressed
Myrbetriq	Mirabegron	24	suppressed
Valproic Acid	Valproic Acid (As Sodium Salt)	24	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	23	suppressed
Carbamazepine	Carbamazepine	22	suppressed
Simvastatin	Simvastatin	22	suppressed
Clonidine Hcl	Clonidine Hcl	21	suppressed
Duloxetine Hcl	Duloxetine Hcl	21	suppressed
Farxiga	Dapagliflozin Propanediol	21	suppressed
Buspirone Hcl	Buspirone Hcl	19	suppressed
Glipizide Er	Glipizide	18	suppressed
Humalog	Insulin Lispro	17	suppressed
Insulin Aspart Flexpen	Insulin Aspart	17	suppressed
Lactulose	Lactulose	17	suppressed
Alprazolam	Alprazolam	16	suppressed
Amiodarone Hcl	Amiodarone Hcl	16	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	16	suppressed
Securesafe Pen Needle	Pen Needle, Diabetic, Safety	16	suppressed
Allopurinol	Allopurinol	15	suppressed
Glimepiride	Glimepiride	15	suppressed
Olanzapine	Olanzapine	15	suppressed
Diltiazem 24hr Er (Xr)	Diltiazem Hcl	13	suppressed
Metformin Hcl Er	Metformin Hcl	13	suppressed
Nystop	Nystatin	13	suppressed
Primidone	Primidone	13	suppressed
Raloxifene Hcl	Raloxifene Hcl	13	suppressed
Risperidone	Risperidone	13	suppressed
Valsartan	Valsartan	13	suppressed
Ezetimibe	Ezetimibe	12	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	12	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Nystatin	Nystatin	12	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Pravastatin Sodium	Pravastatin Sodium	12	suppressed
Alendronate Sodium	Alendronate Sodium	11	suppressed
Atenolol	Atenolol	11	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	11	suppressed
Cholestyramine Light	Cholestyramine	11	suppressed
Clonazepam	Clonazepam	11	suppressed
Memantine Hcl Er	Memantine Hcl	11	suppressed
Oxycodone Hcl	Oxycodone Hcl	11	suppressed
Pentoxifylline	Pentoxifylline	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error